Manzoor Saika, Ganie Mohd A, Majid Sabhiya, Shabir Iram, Kawa Iram A, Fatima Qudsia, Jeelani Humira, Yousuf Syed Douhath, Rashid Fouzia
Department of Clinical Biochemistry/Biochemistry, University of Kashmir, Hazratbal, Srinagar, J&K 190006 India.
Department of Endocrinology and Metabolism, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, J&K India.
Indian J Clin Biochem. 2021 Jul;36(3):278-287. doi: 10.1007/s12291-020-00901-w. Epub 2020 Jun 17.
Human polycystic ovary syndrome (PCOS)-a cluster of diseases displays various symptoms associated with endocrine and gynecological disorders in childbearing women. Oral contraceptive pills (OCP) being a drug of choice minimizes symptoms and complications associated with the disorder. But, the controversial data available in literature regarding use of OCPs compels us to setup a study design regarding effect of OCP treatment in PCOS subjects and the possible outcomes specifically regarding coagulation pathways. Two PCOS study groups have been selected according to Rotterdam Criteria: one with OCP treatment (n = 50) and other without any drug treatment i.e., drug naive (n = 50). Anthropometry, Biochemistry, Hormones, Insulin and various clotting factors like Factor XI, Factor V, tPA, TAT-III and D-dimer were analyzed in both groups. The results showed worsening of IR, Metabolic parameters and coagulopathy in OCP group comparative to drug naive group indicating adverse effects of the OCP treatment which puts these women at risk for number of future clinical implications especially Cardiovascular and metabolic complications.
人类多囊卵巢综合征(PCOS)——一组疾病,在育龄女性中表现出与内分泌和妇科疾病相关的各种症状。口服避孕药(OCP)作为首选药物可使与该疾病相关的症状和并发症降至最低。但是,文献中关于使用OCP的有争议的数据促使我们设计一项关于OCP治疗对PCOS患者的影响以及特别是关于凝血途径的可能结果的研究。根据鹿特丹标准选择了两个PCOS研究组:一组接受OCP治疗(n = 50),另一组未接受任何药物治疗,即未用药组(n = 50)。对两组进行了人体测量、生化、激素、胰岛素以及各种凝血因子如因子XI、因子V、组织型纤溶酶原激活物(tPA)、凝血酶抗凝血酶复合物III(TAT - III)和D - 二聚体的分析。结果显示,与未用药组相比,OCP组的胰岛素抵抗(IR)、代谢参数和凝血病恶化,表明OCP治疗的不良反应,这使这些女性面临许多未来临床问题的风险,尤其是心血管和代谢并发症。